EGFR mutations in non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Lancet Oncology

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(10)70065-6PMID 20434712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients

  2009cited by this paper
• Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.

  2009cited by this paper
• Breast cancer metastases are molecularly distinct from their primary tumors

  2008cited by this paper
• Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

  2007cited by this paper
• A molecular signature of metastasis in primary solid tumors

  2003cited by this paper

• Innovative Amino-Functionalization of Pyrido[2,3-d]pyrimidine Scaffolds for Broad Therapeutic Applications Supported by Computational Analyses

  2025cites this paper
• Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

  2025cites this paper
• Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies

  2025cites this paper
• Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from Lung Cancer Patients.

  2025cites this paper
• Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

  2024cites this paper
• ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection

  2023cites this paper
• Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release

  2023cites this paper
• E3 ubiquitin ligases in lung cancer: Emerging insights and therapeutic opportunities.

  2023cites this paper
• A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations

  2022cites this paper
• Descriptor-free QSAR: effectiveness in screening for putative inhibitors of FGFR1

  2022cites this paper
• PNA Clamping in Nucleic Acid Amplification Protocols to Detect Single Nucleotide Mutations Related to Cancer

  2020cites this paper
• The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer

  2020cites this paper
• The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer

  2017cites this paper
• Targeting FGFR in Squamous Cell Carcinoma of the Lung

  2017cites this paper
• Analytic and Clinical Validation of an Ultrasensitive, Quantitative Polymerase Chain Reaction Assay for EGFR Mutation Analysis With Circulating Tumor DNA.

  2017cites this paper
• IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.

  2016cites this paper
• SIFORM: shared informative factor models for integration of multi-platform bioinformatic data

  2016cites this paper
• INTEGRATION OF MULTI-PLATFORM HIGH-DIMENSIONAL OMIC DATA

  2016cites this paper
• B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer

  2014cites this paper
• Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.

  2011cites this paper
• The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.

  2011cites this paper
• Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing

  2011cites this paper
• Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations

  2010cites this paper
• EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors.

  2009cites this paper
• Immunotherapy in the landscape of new targeted treatments for non‐small cell lung cancer

  2009cites this paper